论文部分内容阅读
已批准新药FDA批准Pravachol用于儿童患者 2002年10月31日,百时美-施贵宝公司宣布FDA批准Pravachol(r)(普伐他汀钠)用于治疗杂合型家族性高胆固醇(HeFH)儿童患者。8周岁以上罹患此病的儿童以及在正常进食试验后LDL水平偏高的儿童均在这一新适应症范围内。
Approved New Drug FDA Approves Pravachol for Pediatric Patients Bristol-Myers Squibb announces FDA approval of Pravachol (r) (pravastatin sodium) for the treatment of children with heterozygous familial hypercholesterolemia (HeFH) on October 31, 2002 patient. Children over 8 years of age with this disease and those with high LDL levels after a normal feeding test are within this new indication.